-

01:35:24 PM

LIVE Real Time GTHX Stock Market News

GTHX - G1 Therapeutics Inc

04/07/21 7:00 AM

Nasdaq : GTHX

G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in the 20th Annual Needham Virtual Healthcare Conference. The fireside chat

RHEA-AI

neutral

04/02/21 4:05 PM

Nasdaq : GTHX

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1's common stock to eight employees under the G1

RHEA-AI

very positive

04/01/21 7:30 AM

Nasdaq : GTHX

G1 Therapeutics to Host Virtual COSELA(TM) (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Kickoff Analyst and Investor Summit on Friday, April 9, 2021 from 9:00 a.m. to 11:00 a.m. EDT. G1

RHEA-AI

negative

03/25/21 6:50 AM

Nasdaq : GTHX

G1 Therapeutics' COSELA(TM) (trilaciclib) Included in Two Updated National Comprehensive Cancer Network(R) (NCCN) Clinical Practice Guidelines in Oncology

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today

RHEA-AI

neutral

03/05/21 4:05 PM

Nasdaq : GTHX

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 14,300 shares of G1's common stock to two employees under the G1

RHEA-AI

very positive

03/03/21 7:30 AM

Nasdaq : GTHX

G1 Therapeutics to Participate in Two Investor Conferences in March

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March. Jack Bailey, G1's Chief Executive Officer, will provide a

RHEA-AI

neutral

03/02/21 6:59 AM

Nasdaq : GTHX

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA(TM) (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

RHEA-AI

neutral

02/24/21 4:01 PM

Nasdaq : GTHX

G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

- G1's COSELA(TM) (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March - - Launch Underway, including Medical Affairs, Promotional, and Educational Activities to Introduce COSELA to

RHEA-AI

neutral

02/17/21 8:00 AM

Nasdaq : GTHX

G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 2020 on Wednesday, February 24,

RHEA-AI

neutral

02/12/21 7:40 PM

Nasdaq : GTHX

FDA Approves G1 Therapeutics' COSELA(TM) (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy - - Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe

RHEA-AI

neutral